Skip to content
Open access

Decoding the Antibody Reactome at Scale with Novel Antigen Display Technology to Decipher Immune History 2335216

Jul 2026 · Journal of Immunology · Vol 215 · 0 citations

TL;DR

The MIPSA technology offers a scalable, high-resolution solution for uncovering immune insights offering a comprehensive view of immune history, this platform facilitates the discovery of novel biomarkers, infectious triggers of chronic conditions, the characterization of host-pathogen interactions, and the development of more effective therapeutic interventions for human health.

Abstract

The human immune system serves as a ledger of environmental exposures, infections, and self-reactivity and there is a there is a critical need for high-throughput tools capable of mapping the entire human antibody reactome (all the antibody-antigen interactions). However, capturing the entire “immune history” can be difficult as conventional assays are limited to a narrow set of defined antigens. Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology employs a single-pot process to create libraries with antigens are covalently linked to unique DNA barcodes and decoded via Next-Generation Sequencing. This multiplexed, sample-sparing approach enables the simultaneous profiling of tens of thousands of interactions via core libraries: (1) HuSIGHT, covering the human proteome with 353,034 peptides and 16,516 full-length proteins; (2) VirSIGHT, covering all viruses known to infect humans with 285,669 peptides; and (3) EnviroSIGHT, covering 1,207 genera of allergens, microbial antigens, and toxins with 242,884 peptides. Using commercial monoclonal antibodies and serum from patients with confirmed autoimmune diseases, the inclusion of both peptides and full-length proteins increases the detection of autoantibody targets on HuSIGHT. Profiling with VirSIGHT effectively distinguished “common” viral signatures from unique exposure histories. Furthermore, EnviroSIGHT allowed for the discrimination of distinct allergic profiles and geographical locations based on endemic pathogen exposure of the participants. We validated the platform’s robustness against technical and clinical confounders. The MIPSA technology offers a scalable, high-resolution solution for uncovering immune insights offering a comprehensive view of immune history, this platform facilitates the discovery of novel biomarkers, infectious triggers of chronic conditions, the characterization of host-pathogen interactions, and the development of more effective therapeutic interventions for human health. n/a Technological Innovations in Immunology (TECH)

Read PDF

Similar papers

Open access Oct 2026

SEEKER: A genome-scale library-on-library screening platform for deciphering T cell recognition of antigen

Decoding which antigens activate a given T cell receptor (TCR) is a central challenge in immunology. We present SEEKER, a functional genome-scale library-on-library screening platform built on three elements: a Jurkat-derived T-APC cell (TAPCell) that combinatorially expresses one TCR and one peptide–MHC drawn from sep...

Si-Cheng Li, Li Lin, Wen-Xu Wu et al. · 0 citations
Aug 2026

High-Throughput On-Chip Screening Enables Rapid Adaptation of DNA Aptamers to SARS-CoV-2 Evolution.

A high-throughput aptamer engineering platform that combines a random-rational hybrid library diversification with repurposed MiSeq screening to rapidly reprogram aptamers against emerging SARS-CoV-2 spike variants is demonstrated, demonstrating a rapid and sequence-resolved aptamer engineering platform for adapting ap...

Yu-Jie He, Zhenglin Yang, Yu-An Kuo et al. · 0 citations
Open access Sep 2026

Discovery of rare antigen-specific TCRs via replicate profiling

Development of effective vaccines and targeted immunotherapies for cancer, autoimmunity, allergy, and infectious diseases requires comprehensive understanding of functionality and antigenic specificity of involved T cell clones. A major technical challenge remains the high-throughput identification of antigen-speci...

E. Egorov, V. Kriukova, I. Shagina et al. · 0 citations
Open access Sep 2026

Development and application of nbLIBRA-seq for high-throughput discovery of antigen-specific nanobodies.

The successful adaptation of linking B cell receptor to antigen specificity through sequencing (LIBRA-seq) to immunized alpacas for the rapid identification of antigen-specific nanobodies, derived from heavy-chain antibodies, is demonstrated.

Sabina E. W. Leonard, Perry T. Wasdin, Katherine Webb et al. · 0 citations
Sep 2026

Digital Nanopore Counting Enabling Direct Identification of Trace-Level Neoantigens in Native Biological Samples

The limit of quantification is improved to the fmol level in native biological environments, enabling the direct identification of neoantigens from as few as 5000 cells within 30 min, and the identification of a native Epstein–Barr virus-associated neoantigen is demonstrated.

Yan Gao, Yun-Ze Wu, Jie Jiang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.